Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News TCT 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Michael O'Riordan

October 19, 2020

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2012

A Preview to OPTIMIZE

Presenter: Fausto Feres

October 22, 2012

Advertisement

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

A Preview to OPTIMIZE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content